Point-of-use mixing of influenza H5N1 vaccine and MF59 adjuvant for pandemic vaccination preparedness: antibody responses and safety. A phase 1 clinical trial
MJ Mulligan, DI Bernstein, S Frey… - Open forum …, 2014 - academic.oup.com
Abstract Background. Avian influenza A/H5N1 has threatened human health for nearly 2
decades. Avian influenza A vaccine without adjuvant is poorly immunogenic. A flexible rapid …
decades. Avian influenza A vaccine without adjuvant is poorly immunogenic. A flexible rapid …
Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial …
MJ Mulligan, DI Bernstein, S Frey… - Open Forum …, 2014 - search.ebscohost.com
Abstract Background. Avian influenza A/H5N1 has threatened human health for nearly 2
decades. Avian influenza A vaccine without adjuvant is poorly immunogenic. A flexible rapid …
decades. Avian influenza A vaccine without adjuvant is poorly immunogenic. A flexible rapid …
[PDF][PDF] Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 …
MJ Mulligan, DI Bernstein, S Frey, P Winokur… - 2014 - Citeseer
Background. Avian influenza A/H5N1 has threatened human health for nearly 2 decades.
Avian influenza A vaccine without adjuvant is poorly immunogenic. A flexible rapid tactic for …
Avian influenza A vaccine without adjuvant is poorly immunogenic. A flexible rapid tactic for …
Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial …
MJ Mulligan, DI Bernstein, S Frey… - Open Forum …, 2014 - europepmc.org
Background Avian influenza A/H5N1 has threatened human health for nearly 2 decades.
Avian influenza A vaccine without adjuvant is poorly immunogenic. A flexible rapid tactic for …
Avian influenza A vaccine without adjuvant is poorly immunogenic. A flexible rapid tactic for …
Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial
MJ Mulligan, DI Bernstein, S Frey… - Open forum …, 2014 - pubmed.ncbi.nlm.nih.gov
Background Avian influenza A/H5N1 has threatened human health for nearly 2 decades.
Avian influenza A vaccine without adjuvant is poorly immunogenic. A flexible rapid tactic for …
Avian influenza A vaccine without adjuvant is poorly immunogenic. A flexible rapid tactic for …
[PDF][PDF] Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 …
MJ Mulligan, DI Bernstein, S Frey, P Winokur… - 2014 - cyberleninka.org
Background. Avian influenza A/H5N1 has threatened human health for nearly 2 decades.
Avian influenza A vaccine without adjuvant is poorly immunogenic. A flexible rapid tactic for …
Avian influenza A vaccine without adjuvant is poorly immunogenic. A flexible rapid tactic for …
[HTML][HTML] Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 …
MJ Mulligan, DI Bernstein, S Frey… - Open Forum …, 2014 - ncbi.nlm.nih.gov
Background Avian influenza A/H5N1 has threatened human health for nearly 2 decades.
Avian influenza A vaccine without adjuvant is poorly immunogenic. A flexible rapid tactic for …
Avian influenza A vaccine without adjuvant is poorly immunogenic. A flexible rapid tactic for …
[PDF][PDF] Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 …
MJ Mulligan, DI Bernstein, S Frey, P Winokur… - 2014 - researchgate.net
Background. Avian influenza A/H5N1 has threatened human health for nearly 2 decades.
Avian influenza A vaccine without adjuvant is poorly immunogenic. A flexible rapid tactic for …
Avian influenza A vaccine without adjuvant is poorly immunogenic. A flexible rapid tactic for …
[PDF][PDF] Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 …
MJ Mulligan, DI Bernstein, S Frey, P Winokur… - 2014 - pdfs.semanticscholar.org
Background. Avian influenza A/H5N1 has threatened human health for nearly 2 decades.
Avian influenza A vaccine without adjuvant is poorly immunogenic. A flexible rapid tactic for …
Avian influenza A vaccine without adjuvant is poorly immunogenic. A flexible rapid tactic for …
[PDF][PDF] Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 …
MJ Mulligan, DI Bernstein, S Frey… - Open Forum …, 2014 - academic.oup.com
Abstract Background. Avian influenza A/H5N1 has threatened human health for nearly 2
decades. Avian influenza A vaccine without adjuvant is poorly immunogenic. A flexible rapid …
decades. Avian influenza A vaccine without adjuvant is poorly immunogenic. A flexible rapid …